178 related articles for article (PubMed ID: 33524928)
1. Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment.
Gómez-Moreno M; Sánchez-Seco VG; Moreno-García S; Cámara PS; Sabin-Muñoz J; Ayuso-Peralta L; Oreja-Guevara C; Díaz-Díaz J; Sainz de la Maza S; Costa-Frossard L; Pilo de la Fuente B; Aladro-Benito Y
Mult Scler Relat Disord; 2021 Apr; 49():102747. PubMed ID: 33524928
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y;
J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647
[TBL] [Abstract][Full Text] [Related]
3. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
4. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
Wood CH; Robertson NP; Htet ZM; Tallantyre EC
Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
[TBL] [Abstract][Full Text] [Related]
5. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
Mallucci G; Annovazzi P; Miante S; Torri-Clerici V; Matta M; La Gioia S; Cavarretta R; Mantero V; Costantini G; D'Ambrosio V; Zaffaroni M; Ghezzi A; Perini P; Rossi S; Bertolotto A; Rottoli MR; Rovaris M; Balgera R; Cavalla P; Montomoli C; Bergamaschi R
J Neurol; 2018 Aug; 265(8):1850-1859. PubMed ID: 29948245
[TBL] [Abstract][Full Text] [Related]
6. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
8. [Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis].
de Sá J; Ferreira J; Macedo AM
Rev Neurol; 2023 Jan; 76(s01):S1-S6. PubMed ID: 36683265
[TBL] [Abstract][Full Text] [Related]
9. Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese Population.
Barros A; Sequeira J; de Sousa A; Parra J; Brum M; Pedrosa R; Capela C
Clin Neuropharmacol; 2020; 43(3):55-60. PubMed ID: 32384308
[TBL] [Abstract][Full Text] [Related]
10. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
11. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
[TBL] [Abstract][Full Text] [Related]
12. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
14. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W; Kansal A; Vicente C; Deniz B; Sarda S
J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
[TBL] [Abstract][Full Text] [Related]
17. Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report.
Ciurleo R; Sessa E; Marino S; D'Aleo G; Bramanti P; Rifici C
Medicine (Baltimore); 2019 Apr; 98(17):e15185. PubMed ID: 31027063
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
Mirabella M; Prosperini L; Lucchini M; Boffa L; Borriello G; Buscarinu MC; Centonze D; Cortese A; De Fino C; De Giglio L; Elia G; Fantozzi R; Ferraro E; Francia A; Galgani S; Gasperini C; Haggiag S; Landi D; Marfia GA; Millefiorini E; Monteleone F; Nociti V; Salvetti M; Sgarlata E; Pozzilli C
CNS Drugs; 2018 Oct; 32(10):963-970. PubMed ID: 30022464
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]